-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Sinopharm Holding released the unaudited financial information for the three months ended March 31, 2022.
The group achieved operating income of RMB 127.
598 billion (the same unit below), an increase of 6.
1% year-on-year; The net profit attributable to owners of the parent company was 1.
428 billion yuan, a year-on-year increase of 17.
41%; basic earnings per share were 0.
46 yuan
.
Coincidentally, before this, China Resources Pharmaceutical also disclosed the first quarter results of three subsidiaries in 2022 on the Hong Kong Stock Exchange
.
Among them, China Resources Sanjiu achieved an operating income of 4.
194 billion yuan (RMB, the same below), a year-on-year increase of 2.
81%; a net profit of 846 million yuan, a year-on-year increase of 30.
53%; Jiangzhong Pharmaceutical achieved an operating income of 931 million yuan, a year-on-year increase of 37.
38%; The net profit was 194 million yuan, a year-on-year increase of 19.
41%; China Resources Boya Bio achieved a total operating income of about 655 million yuan, a year-on-year increase of 4.
89%; net profit was 107 million yuan, a year-on-year increase of 2.
79%
.
In addition, on April 25, Jointown also released a first-quarter results announcement saying that the revenue in the first quarter of 2022 will be about 35.
15 billion yuan; the net profit will be about 452 million yuan; and the basic earnings per share will be 0.
23 yuan
.
As of now, three of the four major pharmaceutical distribution companies have announced their first quarter results in 2022
.
Although Shanghai Pharmaceuticals has not released its first-quarter performance report, judging from its previously announced results for 2021, the industry expects that the trend will continue in the first quarter of this year
.
It is understood that Shanghai Pharmaceuticals achieved revenue of RMB 215.
825 billion last year (the same unit below), a year-on-year increase of 12.
46%; the profit attributable to the company's owners was 5.
093 billion yuan, a year-on-year increase of 13.
28%
.
Comprehensively comparing the first quarter reports of the four major pharmaceutical distribution giants, we can see that in 2022, the centralized procurement of pharmaceutical consumables will develop steadily towards normalization, the implementation of "dual channels", and the accelerated outflow of prescriptions will bring or more or less benefit
.
In addition, a series of policies that have been promulgated by the state are beneficial to the development of pharmaceutical circulation, such as the "Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry during the "14th Five-Year Plan" Period, "The 14th Five-Year Plan for the Development of Digital Economy", " With the help of the "14th Five-Year Plan for Cold Chain Logistics Development", etc.
, it has also brought positive impacts to the business development of distribution enterprises in many aspects
.
In this context, the industry believes that pharmaceutical distribution companies need to accelerate transformation and upgrading in order to better grasp the development trend of drug retail chain, specialization, diversification, and specialization, become more refined, specialized, bigger and stronger, and meet the needs of multi-level Health consumer market demand
.
After all, in the past, China's pharmaceutical distribution industry had the characteristics of a large number of enterprises but a generally small scale.
However, the industry market concentration was too low and there were too many circulation links, resulting in the industry's weak overall competitiveness and weak profitability
.
Therefore, with the in-depth implementation of various policies, the general trend of accelerating the reshuffling and integration of the entire industry will continue.
Only by accelerating transformation and upgrading and improving competitiveness can pharmaceutical distribution companies better cope with the pressures they will face in the future and gain access to More development opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The group achieved operating income of RMB 127.
598 billion (the same unit below), an increase of 6.
1% year-on-year; The net profit attributable to owners of the parent company was 1.
428 billion yuan, a year-on-year increase of 17.
41%; basic earnings per share were 0.
46 yuan
.
Coincidentally, before this, China Resources Pharmaceutical also disclosed the first quarter results of three subsidiaries in 2022 on the Hong Kong Stock Exchange
.
Among them, China Resources Sanjiu achieved an operating income of 4.
194 billion yuan (RMB, the same below), a year-on-year increase of 2.
81%; a net profit of 846 million yuan, a year-on-year increase of 30.
53%; Jiangzhong Pharmaceutical achieved an operating income of 931 million yuan, a year-on-year increase of 37.
38%; The net profit was 194 million yuan, a year-on-year increase of 19.
41%; China Resources Boya Bio achieved a total operating income of about 655 million yuan, a year-on-year increase of 4.
89%; net profit was 107 million yuan, a year-on-year increase of 2.
79%
.
In addition, on April 25, Jointown also released a first-quarter results announcement saying that the revenue in the first quarter of 2022 will be about 35.
15 billion yuan; the net profit will be about 452 million yuan; and the basic earnings per share will be 0.
23 yuan
.
As of now, three of the four major pharmaceutical distribution companies have announced their first quarter results in 2022
.
Although Shanghai Pharmaceuticals has not released its first-quarter performance report, judging from its previously announced results for 2021, the industry expects that the trend will continue in the first quarter of this year
.
It is understood that Shanghai Pharmaceuticals achieved revenue of RMB 215.
825 billion last year (the same unit below), a year-on-year increase of 12.
46%; the profit attributable to the company's owners was 5.
093 billion yuan, a year-on-year increase of 13.
28%
.
Comprehensively comparing the first quarter reports of the four major pharmaceutical distribution giants, we can see that in 2022, the centralized procurement of pharmaceutical consumables will develop steadily towards normalization, the implementation of "dual channels", and the accelerated outflow of prescriptions will bring or more or less benefit
.
In addition, a series of policies that have been promulgated by the state are beneficial to the development of pharmaceutical circulation, such as the "Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry during the "14th Five-Year Plan" Period, "The 14th Five-Year Plan for the Development of Digital Economy", " With the help of the "14th Five-Year Plan for Cold Chain Logistics Development", etc.
, it has also brought positive impacts to the business development of distribution enterprises in many aspects
.
In this context, the industry believes that pharmaceutical distribution companies need to accelerate transformation and upgrading in order to better grasp the development trend of drug retail chain, specialization, diversification, and specialization, become more refined, specialized, bigger and stronger, and meet the needs of multi-level Health consumer market demand
.
After all, in the past, China's pharmaceutical distribution industry had the characteristics of a large number of enterprises but a generally small scale.
However, the industry market concentration was too low and there were too many circulation links, resulting in the industry's weak overall competitiveness and weak profitability
.
Therefore, with the in-depth implementation of various policies, the general trend of accelerating the reshuffling and integration of the entire industry will continue.
Only by accelerating transformation and upgrading and improving competitiveness can pharmaceutical distribution companies better cope with the pressures they will face in the future and gain access to More development opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
